Eli Lilly and Company has reported compelling results from its Phase 3 BRUIN CLL-313 trial evaluating Jaypirca (pirtobrutinib) in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study showed that Jaypirca reduced the risk of disease progression or death by 80 percent compared to bendamustine plus rituximab. These findings were featured in a late-breaking presentation at the 2025 American Society of Hematology Annual Meeting and simultaneously published in the Journal of Clinical Oncology.
Why this data puts pirtobrutinib ahead in the BTK inhibitor race
The BRUIN CLL-313 trial marks the first time a non-covalent Bruton tyrosine kinase inhibitor has outperformed traditional chemoimmunotherapy in treatment-naïve patients. The hazard ratio for progression-free survival was 0.20, indicating a profound risk reduction. While covalent BTK inhibitors like ibrutinib and acalabrutinib have dominated the space in relapsed or refractory settings, resistance mutations and tolerability issues have long plagued their use.
Jaypirca’s design as a non-covalent, reversible inhibitor was originally intended to circumvent these resistance mechanisms. The BRUIN CLL-313 data now offer the first direct proof that this next-generation mechanism can also deliver superior efficacy in first-line treatment. This could upend current sequencing strategies and elevate pirtobrutinib to a frontline standard in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Why chemoimmunotherapy may no longer be enough in CLL
Bendamustine plus rituximab, while historically important in frontline CLL, is now being outpaced by targeted therapies in both efficacy and tolerability. The trial enrolled 282 patients without 17p deletions, randomly assigning them to either Jaypirca monotherapy or BR. The results strongly favored Jaypirca not just in the overall population but across all prespecified high-risk subgroups, including patients with TP53 mutations, complex karyotype, and unmutated IGHV.
This suggests that non-covalent BTK inhibitors could offer broader efficacy across genetically diverse CLL profiles. The consistency of Jaypirca’s benefit in both independent review and investigator assessments adds weight to the argument that chemoimmunotherapy may no longer justify its risk-benefit trade-off in most first-line scenarios.
How the safety profile changes the calculus for clinicians
Safety has always been a key barrier to wider use of BTK inhibitors in earlier lines. In BRUIN CLL-313, treatment-emergent adverse events of grade 3 or higher occurred in just 40 percent of Jaypirca-treated patients compared to 67.4 percent in the BR arm. Fewer dose reductions and discontinuations were reported, with only 4.3 percent of patients needing to stop Jaypirca due to side effects. Importantly, atrial fibrillation and flutter were comparable between both arms, despite Jaypirca’s class association.
This level of tolerability is especially relevant for older CLL patients or those with comorbid conditions. The ability to administer a once-daily oral therapy with fewer interruptions or complications could meaningfully alter patient experience, adherence, and outcomes. In community oncology settings where monitoring resources are limited, such a safety profile could be decisive.
What regulatory agencies will be watching in the final OS data
Overall survival was a key secondary endpoint in BRUIN CLL-313 but remains immature. A positive trend was observed, with a hazard ratio of 0.257. However, the study’s crossover design complicates interpretation. More than half of patients in the BR arm switched to Jaypirca after disease progression, which may dilute the final survival signal. Regulators will likely require further maturity in the data before granting full label expansion, especially in first-line settings.
Still, the early signal supports the hypothesis that initiating treatment with pirtobrutinib may offer not just progression delay but also potential survival benefit. Lilly has begun submitting these data to regulatory agencies globally, suggesting confidence in eventual approval. If confirmed, the expansion of Jaypirca into earlier disease stages could arrive in 2026.
What this could mean for treatment sequencing in hematologic oncology
A critical strategic shift may be underway in how clinicians approach BTK inhibitor sequencing. Until now, non-covalent BTK inhibitors have largely been used as salvage therapies for patients who progressed on covalent agents. BRUIN CLL-313 upends that narrative by demonstrating superior efficacy for pirtobrutinib in BTK-inhibitor-naïve patients.
If Jaypirca becomes the new standard of care in the frontline setting, it could compress treatment lines and create new gaps in the sequencing logic. The oncology community will need to consider what agents follow Jaypirca in the event of relapse, as post-pirtobrutinib resistance mechanisms are not yet fully understood. This may accelerate interest in combination regimens or trials that incorporate BCL-2 inhibitors and monoclonal antibodies from the start.
How Lilly is positioning Jaypirca as a cornerstone franchise
Eli Lilly and Company is executing a deliberate franchise strategy around Jaypirca, aiming to secure a presence in multiple CLL settings. Having already received U.S. Food and Drug Administration approval for relapsed or refractory CLL and mantle cell lymphoma, Lilly is now building clinical evidence across earlier lines of therapy. BRUIN CLL-313 complements data from BRUIN CLL-314, which evaluated Jaypirca post-covalent BTK inhibitor failure.
By anchoring both ends of the treatment spectrum, Lilly appears to be positioning pirtobrutinib as a foundational agent akin to how lenalidomide or venetoclax function in their respective indications. The depth of trial design, including randomized head-to-head comparisons, may give regulators and payers greater comfort with broad label expansion.
This approach may also insulate the company from competition by staking out territory early. Emerging BTK inhibitors or novel agents will need to demonstrate not just superiority to older covalent inhibitors, but direct competitiveness with Jaypirca in newly diagnosed patients.
What could slow down Jaypirca’s dominance in first-line CLL
Despite the strength of the BRUIN CLL-313 data, several unresolved issues could temper enthusiasm. The long-term durability of Jaypirca remains under evaluation. Unlike covalent inhibitors, which have been in widespread use for over a decade, pirtobrutinib does not yet have multi-year follow-up data in the first-line population. There is also uncertainty around resistance mechanisms that may emerge with prolonged use in treatment-naïve patients.
Commercially, competition is intensifying. Zanubrutinib, another BTK inhibitor, has generated strong results in CLL and may be preferred in certain subgroups. Venetoclax-based combinations remain a strong contender in time-limited treatment paradigms. If pirtobrutinib cannot demonstrate advantage in time to next treatment or overall survival in future analyses, some physicians may opt for fixed-duration alternatives.
Lastly, pricing and reimbursement will play a role. If Jaypirca is positioned at a premium relative to ibrutinib or generic BR, payers may scrutinize its use without overall survival superiority. Health technology assessments in Europe and cost-effectiveness modeling in the U.S. may be required to justify frontline adoption.
Conclusion: a milestone moment, but still early innings
The BRUIN CLL-313 trial delivers a landmark result for non-covalent BTK inhibition, positioning Jaypirca as a potential first-line therapy in chronic lymphocytic leukemia. The data reset expectations for what a single-agent oral therapy can achieve in terms of progression-free survival and tolerability. However, the full commercial, regulatory, and clinical impact will depend on maturing survival data, resistance profiles, and competitive positioning over the next 12 to 24 months.
Eli Lilly and Company has placed itself at the center of a high-stakes shift in hematologic oncology. Whether pirtobrutinib becomes the new foundation of BTK therapy or one among several viable options will depend on how the data and the market evolve in parallel.
Is Eli Lilly’s Jaypirca now the most compelling single-agent therapy in untreated CLL? added by Srinath B on
View all posts by Srinath B →